Anidulafungin versus fluconazole for invasive candidiasis.
about
Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unitInvasive candidiasis as a cause of sepsis in the critically ill patientAntifungal therapy in infants and children with proven, probable or suspected invasive fungal infectionsRole of isavuconazole in the treatment of invasive fungal infectionsClinical perspectives on echinocandin resistance among Candida speciesSingle or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!Echinocandin resistance: an emerging clinical problem?Intensive care medicine research agenda on invasive fungal infection in critically ill patients.Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational studyAnidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patientsSafety and Efficacy of Anidulafungin for Fungal Infection in Patients With Liver Dysfunction or Multiorgan FailureClinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of AmericaInvasive fungal infections in transplant recipientsNovel FKS mutations associated with echinocandin resistance in Candida species.Clinical factors associated with a Candida albicans Germ Tube Antibody positive test in Intensive Care Unit patientsIn vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.Fungal infections in transplant and oncology patients.Breakthrough invasive candidiasis in patients on micafungin.Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.Echinocandins: the newest class of antifungals.Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theCanadian clinical practice guidelines for invasive candidiasis in adults.Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year periodAntifungal clinical trials and guidelines: what we know and do not knowInvasive fungal infections in solid organ transplant recipients.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control studyClinical hepatotoxicity associated with antifungal agents.Pharmacokinetics and tissue distribution of anidulafungin in rats.Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trialStudy on the effect of neem (Azadirachta indica A. juss) leaf extract on the growth of Aspergillus parasiticus and production of aflatoxin by it at different incubation times.Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study.Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.Management bundles for candidaemia: the impact of compliance on clinical outcomes.Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
P2860
Q21194915-5E9DBBE6-6705-4DE9-888F-002D6A3875E8Q22305429-E5820557-DD94-4C68-B554-17B6327B8ADDQ24239978-3B995BB8-1C4D-4CDA-BB9F-377186A3896BQ26740837-2EC9AEF2-635C-43B4-9CA4-1775303387ECQ28082538-DAAF2FF5-A51A-41C4-8741-B1E3E6FD1C07Q28082570-BF55F969-D164-4C97-A581-F9EB8DD95038Q28544739-1400CB18-FB25-4895-BB6E-86A944C3535DQ30235457-58E943CB-1D3D-4A58-90E5-54210A266E62Q30781344-04478CD1-2952-4A66-9D29-4A1DA4011ABDQ33490772-1102AF40-2A3F-4ADA-8AE0-A0C45D7C4187Q33559503-1A53712E-0D26-46F5-8B14-054827E19B51Q33573788-051E3CC8-78EC-48BD-A487-68D576B7F4E8Q33629353-1ACE0A9A-59EF-4728-A46B-164253EE9729Q33688646-532915DE-800F-48A2-8EAB-841D2E47219CQ33695215-25539F1B-9472-4CF0-AF8F-C94B4555FC3AQ33826330-5C5B7CF9-A3D1-4740-B1F7-12F1F66E3F23Q33841485-9B5156DF-5AEF-4BE0-A330-B6BE9BD434C3Q33876423-DC17B74F-0622-425B-8A76-1A10258060A2Q33876645-EE45976D-86B4-4DF8-89B1-69E54DE8BBB5Q33891810-AC7FF283-327D-4339-8589-6AF73B2A2451Q33896940-B973AADB-E7B6-4B39-B705-DD60094E28B7Q33963538-74F04903-1EDE-4AC0-A20A-A5D0A6D14583Q34006585-11E904AC-9F88-437A-B09A-FEB295768136Q34019188-D4A4EAB6-0768-47BC-9FC8-803A1B02B1EFQ34036214-F4C9170C-8FB6-4E81-BA6B-96D61CAE8F3FQ34212799-ED0482F7-DAF0-4B50-BFE9-8B0E098566C8Q34237335-57A10562-99D3-4D6B-9008-455FCDD0A4F2Q34252030-B545315F-37CF-4FE2-ACF6-2F38072995A6Q34400255-47FCF480-1C69-4D82-8D1E-BD495856F516Q34461693-931A1DD1-94B9-411F-9082-BA9282D12D64Q34505582-3F43C87F-FF69-4DD0-83F1-7C2D3A554695Q34543097-934E441E-1D37-4032-B244-063971BC54F4Q34546811-264C5B87-DD27-4DA4-B7E2-5A7742CA7AF1Q34591184-CC6ACC29-892B-4025-B7A4-2851E4DC6E4DQ34724039-5BEFAA20-A728-4822-9C55-8DD7C933A467Q34724824-A00B4651-7F67-4489-AFA2-D8B3E0BD81D5Q34775518-8538D787-384B-4BA9-9983-A48E368B0230Q34900399-BF0F786E-0ADF-4BE4-8034-585792895490Q34920621-52DA770A-4998-4FC6-B044-4CDCE3489B0BQ34933267-7C9134C7-0170-420E-A781-4F16BDED163B
P2860
Anidulafungin versus fluconazole for invasive candidiasis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Anidulafungin versus fluconazole for invasive candidiasis.
@ast
Anidulafungin versus fluconazole for invasive candidiasis.
@en
Anidulafungin versus fluconazole for invasive candidiasis.
@nl
type
label
Anidulafungin versus fluconazole for invasive candidiasis.
@ast
Anidulafungin versus fluconazole for invasive candidiasis.
@en
Anidulafungin versus fluconazole for invasive candidiasis.
@nl
prefLabel
Anidulafungin versus fluconazole for invasive candidiasis.
@ast
Anidulafungin versus fluconazole for invasive candidiasis.
@en
Anidulafungin versus fluconazole for invasive candidiasis.
@nl
P2093
P356
P1476
Anidulafungin versus fluconazole for invasive candidiasis.
@en
P2093
Anidulafungin Study Group
Annette C Reboli
Beth P Goldstein
Coleman Rotstein
Daniel H Kett
David S Krause
Deepali Kumar
Jennifer Schranz
Michele Wible
Peter G Pappas
P304
P356
10.1056/NEJMOA066906
P407
P577
2007-06-01T00:00:00Z